{"schema_version":"secwatch.filing_event.v1","accession":"0001100682-25-000009","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.932514+00:00","generated_at":"2026-05-26T10:29:35.395768+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Labs Q4 GAAP loss $(4.22) on $215M goodwill impairment; guides FY2025 revenue down 5.5-3.5%","bullets":["Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.","Full-year 2024 revenue $4.05B (-1.9%); non-GAAP EPS $10.32 (-3.3%); GAAP EPS $0.20 (-97.8%).","DSA segment revenue down 3.6% organically; Manufacturing organic +2.1%; RMS organic -0.4% despite Noveprim acquisition.","2025 guidance: organic revenue decline 5.5% to 3.5%; non-GAAP EPS $9.10-$9.60; plans $350M stock repurchase.","CEO cites ongoing biopharma client restructuring; expects stable-to-slightly improved biotech demand in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001100682-25-000009","json":"https://secwatch.observer/filing/0001100682-25-000009.json","markdown":"https://secwatch.observer/filing/0001100682-25-000009.md","text":"https://secwatch.observer/filing/0001100682-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/0001100682-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/crl-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T10:29:35.395768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}